CFI-400945

CAS No. 1338806-73-7

CFI-400945( —— )

Catalog No. M23495 CAS No. 1338806-73-7

CFI-400945 is an potent, selective and orally active inhibitor of polo-like kinase 4(PLK4; Ki value of 0.26 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 77 In Stock
5MG 129 In Stock
10MG 205 In Stock
25MG 397 In Stock
50MG 584 In Stock
100MG 833 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    CFI-400945
  • Note
    Research use only, not for human use.
  • Brief Description
    CFI-400945 is an potent, selective and orally active inhibitor of polo-like kinase 4(PLK4; Ki value of 0.26 nM).
  • Description
    CFI-400945 is an potent, selective and orally active inhibitor of polo-like kinase 4(PLK4; Ki value of 0.26 nM).
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Cell Cycle/DNA Damage
  • Target
    PLK
  • Recptor
    PLK4
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    1338806-73-7
  • Formula Weight
    534.65
  • Molecular Formula
    C33H34N4O3
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:100 mg/mL (187.04 mM;warmed with 50oC water bath);Ethanol:100 mg/mL (187.04 mM);Water:Insoluble
  • SMILES
    C[C@@H]1CN(C[C@@H](O1)C)CC2=CC=C(C=C2)/C=C/C3=NNC4=C3C=CC(=C4)[C@@H]5C[C@]56C7=C(C=CC(=C7)OC)NC6=O
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Mason J , Lin D C , Wei X , et al. Functional Characterization of CFI-400945, a Polo-like Kinase 4 Inhibitor, as a Potential Anticancer Agent[J]. Cancer Cell, 2014, 26(2).
molnova catalog
related products
  • T521

    T521 is a selective inhibitor of the PBD of Plk1 and shows no inhibitory effect on Plk2 and Plk3.

  • RO 3280

    RO3280 is a potent, highly selective inhibitor of Polo-like kinase 1 (PLK1)

  • Poloxin

    Poloxin is a non-ATP competitive Polo-like Kinase 1 inhibitor. It targets the polo-box domain (IC50: appr 4.8 μM).